HPMA copolymer conjugates of paclitaxel and docetaxel with pH-controlled drug release

Molecular Pharmaceutics

Volumn 7, Issue 4, 2010, Pages 1015-1026

  Etrych, Tomáš ^a   Šírovaé, Milada ^b   Starovoytova, L ^a   Řiéhovaé, Blanka ^b   Ulbrich, Karel ^a  

^a INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

^b INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

docetaxel; mammary carcinoma; murine lymphoma; N (2 Hydroxypropyl)methacrylamide (HPMA) copolymer; paclitaxel; tumor resistance

Indexed keywords

3 (ACETYL)ACRYLIC ACID; 4 (2 OXOPROPYL)BENZOIC ACID; ACRYLIC ACID; BENZOIC ACID; CARBONYL DERIVATIVE; DOCETAXEL; LEVULINIC ACID; N (2 HYDROXYPROPYL)METHACRYLAMIDE; OXOACID; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CIRCULATION; CONJUGATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG PURIFICATION; DRUG RELEASE; DRUG SYNTHESIS; ENDOSOME; FEMALE; HYDROLYSIS; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; T CELL LYMPHOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HYDROGEN-ION CONCENTRATION; LYMPHOMA, T-CELL; MALE; METHACRYLATES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; PACLITAXEL; POLYMERS; TAXOIDS;

EID: 77955252647     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp100119f     Document Type: Article

References (48)

1. Duncan, R. Development of HPMA copolymer-anticancer conjugates: Clinical experience and lessons learnt Adv. Drug Delivery Rev. 2009, 61, 1131-1148
2. Ulbrich, K.; Šubr, V.; Strohalm, J.; Plocovaé, D.; Jeliénkovaé, M.; Řiéhovaé, B. Polymeric drugs based on conjugates of synthetic and natural macromolecules: I. Synthesis and physico-chemical characterisation J. Controlled Release 2000, 64, 63-79
3. Pasut, G.; Veronese, F. PEG conjugates in clinical development or use as anticancer agents: An overview Adv. Drug Delivery Rev. 2009, 61, 1177-1188
4. Kratz, F.; Muller, I. A.; Ryppa, C.; Warnecke, A. Prodrug Strategies in Anticancer Chemotherapy ChemMedChem 2008, 3, 20-53
5. 2-targeted conjugates and combined theraphy with immunomodulators J. Controlled Release 2000, 64, 241-261
6. Haag, R.; Kratz, F. Polymer therapeutics: Concepts and applications Angew. Chem., Int. Ed. 2006, 45, 1198-1215
7. Garnet, M. Targeted drug conjugates: principles and progress Adv. Drug Delivery Rev. 2001, 53, 171-216
8. Kopeček, J.; Kopečkovaé, P.; Minko, T.; Lu, Z. R.; Peterson, C. M. Water soluble polymers in tumor targeted delivery J. Controlled Release 2001, 74, 147-158
9. van Dijk-Wolthuis, W. N. E.; van de Wetering, P.; Hinrichs, W. L. J.; Hofmeyer, L. J. F.; Liskamp, R. M. J.; Crommelin, D. J. A.; Hennink, W. E. A Versatile Method for the Conjugation of Proteins and Peptides to Poly[2-(dimethylamino)ethyl methacrylate] Bioconjugate Chem. 1999, 10, 687-692
10. Ulbrich, K.; Strohalm, J.; Šubr, V.; Plocovaé, D. Polymeric Conjugates of Drugs and Antibodies for Site-Specific Drug Delivery Macromol. Symp. 1996, 103, 177-192
11. Putnam, D.; Kopeček, J. Polymer conjugates with anticancer activity Adv. Polym. Sci. 1995, 122, 55-123
12. Ulbrich, K.; Šubr, V. Polymeric anticancer drugs with pH-controlled activation Adv. Drug Delivery Rev. 2004, 56, 1023-1050 (Pubitemid 38520207)
13. Kratz, F.; Beyer, U.; Schutte, M. T. Drug-Polymer Conjugates Containing Acid-Cleavable Bonds Crit. Rev. Ther. Drug Carrier Syst. 1999, 16, 245-288
14. Rodrigues, P.; Roth, T.; Fiebig, H.; Unger, C.; Mülhaupt, R.; Kratz, F. Correlation of the cid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative aktivity Bioorg. Med. Chem. 2006, 14, 4110-4117
15. Diaz, J. F.; Andreu, J. M. Assembly of purified GDP-tubulin into microtubules induced by Taxol and Taxotere: reversibility, ligand stoichiometry, and competition Biochemistry 1993, 32, 2747-2755
16. Bissery, M. C.; Guenard, D.; Gueritte-Voegelein, F.; Lavelle, F. Experimental antitumor activity of Taxotere (RP 56976, NSC 628503), a Taxol analogue Cancer Res. 1991, 51, 4845-4852
17. Belotti, D.; Vergani, V.; Drudis, T.; Borsotti, P.; Pitelli, M. R.; Viale, G.; Giavazzi, R.; Taraboletti, G. The microtubule-affecting drug paclitaxel has antiangiogenic activity Clin. Cancer Res. 1996, 2, 1843-1849
18. Grant, D. S.; Williams, T. L.; Zahaczewsky, M.; Dicker, A. P. Comparison of antiangiogenic activities using paclitaxel (Taxol) and docetaxel (Taxotere) Int. J. Cancer 2003, 104, 121-129
19. Ng, S. S.; Sparreboom, A.; Shaked, Y.; Lee, C.; Man, S.; Desai, N.; Soon-Shiong, P.; Figg, W. D.; Kerbel, R. S. Influence of formulation vehicle on metronomic taxane chemotherapy: albumin-bound versus cremophor EL-based paclitaxel Clin. Cancer Res. 2006, 12, 4331-4338
20. Ibrahim, N. K.; Desai, N.; Legha, S.; Soon-Shiong, P.; Theriault, R. L.; Rivera, E.; Esmaeli, B.; Ring, S. E.; Bedikian, A.; Hortobagyi, G. N.; Ellerhorst, J. A. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel Clin. Cancer Res. 2002, 8, 1038-1044
21. Gradishar, W. J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O'Shaughnessy, J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer J. Clin. Oncol. 2005, 23, 7794-7803 (Pubitemid 46657376)
22. Nyman, D. W.; Campbell, K. J.; Hersh, E.; Long, K.; Richardson, K.; Trieu, V.; Desai, N.; Hawkins, M. J.; Von Hoff, D. D. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies J. Clin. Oncol. 2005, 23, 7785-7793
23. Zheng, D. H.; Li, D.; Lu, X. W.; Feng, Z. Q. Enhanced antitumor efficiency of docetaxel-loaded nanoparticles in a human ovarian xenograft model with lower systemic toxicities by intratumoral delivery Oncol. Rep. 2010, 23, 717-724
24. Feng, S. S.; Mei, I.; Anitha, P.; Gan, C. W.; Zhou, W. Y. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel Biomaterials 2009, 30, 3297-3306
25. Greenwald, R. B.; Gilbert, C. W.; Pendri, A.; Conover, C. D.; Xia, J.; Martinez, A. Drug delivery systems: water soluble Taxol 2a-poly(ethylene glycol) ester prodrugs-design and in vivo effectiveness J. Med. Chem. 1996, 39, 424-431
26. Pendri, A.; Conover, C. D.; Greenwald, R. B. Antitumor activity of paclitaxel-2a-glycinate conjugated to poly(ethylene glycol): a water-soluble prodrug Anti-Cancer Drug Des. 1998, 13, 387-395
27. Singer, J. W.; Shaffer, S.; Baker, B.; Bernareggi, A.; Stromatt, S.; Nienstedt, D.; Besman, M. Paclitaxel poliglumex (XYOTAX; CT-2103): an intracellularly targeted taxane Anti-Cancer Drugs 2005, 16, 243-250
28. Dipetrillo, T.; Milas, L.; Evans, D. Paclitaxel poliglumex (PPX-xyotax) and concurrent radiation for esophageal and gastric cancer-A phase I study Am. J. Clin. Oncol. 2006, 29, 376-379
29. Shaffer, S. A. In vitro and in vivo metabolism of paclitaxel poliglumex: identification of metabolites and active proteases Cancer Chemother. Pharmacol. 2007, 59, 537-548
30. Meerum Terwogt, J. M.; ten Bokkel Huinink, W. W.; Schellens, J. H.; Schot, M.; Mandjes, I. A.; Zurlo, M. G.; Rocchetti, M.; Rosing, H.; Koopman, F. J.; Beijnen, J. H. Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel Anticancer Drugs 2001, 12, 315-323
31. Etrych, T.; Mrkvan, T.; Chytil, P.; Koňaék, C.; Řiéhovaé, B.; Ulbrich, K. N-(2-Hydroxypropyl) methacrylamide-based polymer conjugates with pH-controlled activation of doxorubicin. I. New synthesis, physicochemical characterization and preliminary biological evaluation J. Appl. Polym. Sci. 2008, 109, 3050-3061
32. Etrych, T.; Jelinkovaé, M.; Řiéhovaé, B.; Ulbrich, K. New HPMA copolymers containing doxorubicin bound via pH-sensitive linkage: synthesis and preliminary in vitro and in vivo biological properties J. Controlled Release 2001, 73, 89-102
33. Krakovičovaé, H.; Etrych, T.; Ulbrich, K. HPMA-based polymer conjugates with drug combination Eur. J. Pharm. Sci. 2009, 37, 405-412
34. Řiéhovaé, B.; Etrych, T.; Pechar, M.; Jeliénkovaé, M.; Št'astnyé, M.; Hovorka, O.; Kovaéř, M.; Ulbrich, K. Doxorubicin bound to a HPMA copolymer carrier through hydrazone bond is effective also in a cancer cell line with a limited content of lysosomes J. Controlled Release 2001, 74, 225-232
35. Tannock, I. F.; Rotin, D. Acid pH in tumors and its potential for therapeutic exploitation Cancer Res. 1989, 49, 4373-4384
36. Wouters, B.; Weppler, G.; Koritzinsky, M.; Landuyt, W.; Nuyts, S.; Theys, J.; Chiu, R. K.; Lambin, P. Corresponding Hypoxia as a target forcombined modality treatment Eur. J. Cancer 2002, 38, 240-257
37. Mrkvan, T.; Šiérovaé, M.; Etrych, T.; Chytil, P.; Strohalm, J.; Plocovaé, D.; Ulbrich, K.; Řiéhovaé, B. Chemotherapy based on HPMA copolymer conjugates with pH-controlled release of doxorubicin triggers anti-tumor immunity J. Controlled Release 2005, 110, 119-129
38. Šiérovaé, M.; Strohalm, J.; Šub, V.; Plocovaé, D.; Rossmann, P.; Mrkvan, T.; Ulbrich, K.; Řié hovaé, B. Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice Cancer Immunol. Immunother. 2007, 56, 35-47
39. Kovaéř, M.; Tomala, J.; Chmelovaé, H.; Kovaéř, L.; Joskovaé, R.; Zaékostelskaé, Z.; Etrych, T.; Strohalm, J.; Ulbrich, K.; Řiéhovaé, B. Overcoming Immunoescape Mechanisms of BCL1 Leukemia and Induction of CD8+ T-Cell-Mediated BCL1-Specific Resistance in Mice Cured by Targeted Polymer-Bound Doxorubicin Cancer Res. 2008, 68, 9875-9883
40. Řiéhovaé, B.; Strohalm, J.; Kubaéč kovaé, K.; Jeliénkovaé, M.; Hovorka, O.; Kovaéř, M.; Plocovaé, D.; Šiérovaé, M.; Št'astnyé, M.; Rozprimovaé, L.; Ulbrich, K. Acquired and specific immunological mechanisms co-responsible for efficacy of polymer-bound drugs J. Controlled Release 2002, 78, 97-114
41. Řiéhovaé, B.; Strohalm, J.; Prausovaé, J.; Kubaéčkovaé, K.; Jeliénkovaé, M.; Rozprimovaé, L.; Šiérovaé, M.; Plocovaé, D.; Etrych, T.; Šubr, V.; Mrkvan, T.; Kovaéř, M.; Ulbrich, K. Cytostatic and immunomobilizing activities of polymer-bound drugs: experimental and first clinical data J. Controlled Release 2003, 91, 1-16
42. Vanhoefer, U.; Cao, S.; Harstrick, A.; Seeber, S.; Rustum, Y. M. Comparative antitumor efficacy of docetaxel and paclitaxel in nude mice bearing human tumor xenografts that overexpress the multidrug resistance protein (MRP) Ann. Oncol. 1997, 8, 1221-1228
43. Kovaéř, L.; Etrych, T.; Hovorka, O.; Strohalm, J.; Kabešovaé, M.; Šiérovaé, M.; Větvička, D.; Kovaéř, M.; Ulbrich, K.; Réiéhovaé, B. Immunogenic cancer cell death triggered by free or N-(2-hydroxypropyl)methacrylamide bound doxorubicin, manuscript in preparation.
44. Obeid, M.; Tesniere, A.; Ghiringhelli, F. Calreticulin exposure dictates the immunogenicity of cancer cell death Nat. Med. 2007, 13, 54-61 (Pubitemid 46067386)
45. Apetoh, L.; Ghiringhelli, F.; Tesniere, A. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy Nat. Med. 2007, 13, 1050-59
46. Emens, L. A.; Jaffee, E. M. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy Cancer Res. 2005, 65, 8059-8064
47. Coleman, S.; Clayton, A.; Mason, M. D.; Jasani, B.; Adams, M.; Tabi, Z. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer Cancer Res. 2005, 65, 7000-7006
48. Šiérovaé, M.; Mrkvan, T.; Etrych, T.; Rossmann, P.; Chytil, P.; Ulbrich, K.; Réiéhovaé, B. Polymer prodrugs based on HPMA conjugates with pH-controlled activation of doxorubicin: II. In vivo efficacy Pharm. Res. 2010, 27, 200-208